

The European Research Council



European Research Council


Established by the European Commission

From ERC PoC to EIC Transition An overview

Laura PONTIGGIA





ERC Executive Agency

Support to the Scientific Council




EIC Transition:
Applicants' Day for ERC PoCs
29 March 2021

ERC PoC

 <p>150K EUR</p> <p>Open to all ERC grantees</p>	 <p>Continuous Calls</p> <p>3 cut-off dates/ year</p>	<p>Simple and efficient</p>  <p>7-page proposal</p> <p>18-month project</p>
 <p>Clear selection criteria</p> <p>Focus: breakthrough innovation potential</p>	 <p>Results in 100 days</p> <p>Competent evaluators</p>	 <p>Competitive process</p> <p>36% success rate</p>

A selection process that looks into ideas generated in ERC-funded projects and selects among them the most competitive for translation into a concept to be further developed towards an innovation and/or an entrepreneurial venture


European Innovation: financial support



2011: PoC was created to bridge the Valley of Death




European Research Council
Established by the European Commission



After 10 years: PoC remains closer to idea generation than to innovation

An Empirical Assessment of the ERC PoC

Independent Report 2017



Survey launched to 9,270 PIs of ERC grants (closed 4/12/2020)


1. Have the results of your ERC-funded research directly contributed to the creation of a new company?
2. Have the results of your ERC-funded research been transferred to a preexisting company?

Response rate: 52.6%


Count of User name	
New company?	Total
Don't know	196
No	4406
Yes	273
Grand Total	4875

Count of User name	
Transferred to a preexisting company?	Total
Do not know	195
No	4389
Yes	291
Grand Total	4875


Survey – 273 Company YES




Survey - 291 Transfer YES



New company creation



Survey - Transfer and Company



*10% of the 4,874 PIs responding to the Survey have a PoC

PoC data (2011-2020)




European Research Council

Established by the European Commission

	Budget 10ml	Budget 10ml	Budget 10ml	Budget 15ml	Budget 20ml	Budget 20ml	Budget 20ml	Budget 20ml	Budget 20ml	Budget 25ml	Budget 25ml	
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	TOTAL	
Proposals	139	120	279	426	323	405	497	417	498	513	3617	
Funded	51	60	67	121	160	159	160	160	199	166	1303	
Success	37%	50%	24%	28%	50%	39%	32%	38%	40%	32%	36%	

ERC Proof of Concept 2011-2020





European Research Council
Established by the European Commission



Genenta Science announces 13,2 Million in a New Round of Financing, hits a total above 30 Million since inception. Two clinical trials ongoing.

September 11, 2019

MILANO (Italy) / NEW YORK (NY, USA) – Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem cell gene therapies for cancer (Temferon™), today announced the closing of its third Round adding €13,2M in a total of €30,2M since incorporation. Two Phase I/II clinical trials are currently ongoing in two different indications, early relapse Multiple Myeloma - a hematologic disorder, and newly diagnosed Glioblastoma Multiforme - a solid tumor.

The Round was led by Qianzhan Investment Management (QZ) and Fidim. QZ is a Chinese private investment company based in Shanghai operating in futures trading, stock trading, and private equity investments. Currently, QZ has allocated \$720M to private equity and venture capital in tech and life sciences, investing in China, US and Europe. QZ was one of the first and is currently an investor in Tencent Music (NYSE: TME). QZ is also an investor in Wuhan Hiteck (300683.SZ), Capella Therapeutics (San Diego, CA), Denovo Biopharma (San Diego, CA), among others. Fidim is the holding company of the Rovati family, the former owner of Rottapharm, a pharma company whose commercial activity was acquired by Meda for shares and equity value of €2.2B. Fidim retained the R&D operations as Rottapharm Biotech. In 2016, Meda was acquired by Mylan (NASDAQ: MYL). Both QZ and Fidim will be Observers in Genenta's Board of Directors. QZ will be represented by Jing "Akira"

Number of Acquisitions

1

Total Funding Amount

\$85.9M



Ultrahaptics

Ultrahaptics is working to create the most remarkable connection between people and technology.
Bristol, Bristol, City of, United Kingdom

Categories

Consumer Electronics, Electronics, Software Engineering

Headquarters Regions

European Union (EU)

Founded Date

2013

Founders

Sriram Subramanian, Tom Carter

Operating Status

Active

Funding Status

Late Stage Venture

Last Funding Type

Series C

Number of Employees

51-100

Legal Name

Ultrahaptics Limited

IPO Status

Private

Company Type

For Profit

Website

ultrahaptics.com/

Facebook

[View on Facebook](#)

LinkedIn

[View on LinkedIn](#)

Twitter


[View on Twitter](#)

Contact Email

info@ultrahaptics.com

IQM Finland raises €11.6 million to speed up advancements in quantum computing

By Mary Lortiz - July 9, 2019



Espoo-based IQM Finland is building scalable cryogenic hardware for general purpose quantum computers. The startup—a spinout from Aalto University and VTT Technical Research Centre of Finland (VTT)—is developing high-speed quantum processors using superconducting qubits to reduce the error rates that currently limit quantum computers.



Austrian Cluster for Tissue Regeneration

HOME THE CLUSTER RESEARCH NEWS CONTACT



UpNano wins #glaubandich Challenge

In the great finale of the #glaubandich Challenge, which took place on April 9th in front of more than 1000 spectators, associate Cluster member UpNano was awarded the title Startup of the Year.

The company originates from Aleksandr Ovsianikov's team at TU Vienna. Their patented process allows them to design 3D printers that produce resolutions of less than one micrometer with high production throughput in a cost-effective process. A special feature is the incorporation of living cells during printing. UpNano impressed the crowd and jury of the #glaubandich (German for believe in yourself) Challenge with a strong pitch held by Denise Mandt, co-founder of the company, and of course with its hallmark castle, built on the tip of a sharp pencil (-> read more).

Congratulations from the Cluster!

Total Funding Amount

£557.3M

CB Rank (Company)

3,144



Oxford Nanopore Technologies

Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA and proteins.
Oxford, Oxfordshire, United Kingdom

Categories

Biopharma, Biotechnology, Genetics, Health Diagnostics, Nanotechnology

Headquarters Regions

European Union (EU)

Founded Date

2005

Founders

Gordon Sanghera, Hagan Bayley

Operating Status

Active

Last Funding Type

Venture - Series Unknown

Number of Employees

251-500

Legal Name

Oxford Nanopore Technologies Ltd

Hub Tags

Unicorn

IPO Status

Private

Company Type

For Profit



European Research Council

Established by the European Commission

Thank you!

Laura.Pontiggia@ec.europa.eu